A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Enzalutamide (Primary) ; ZEN 3694 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Newsoara Biopharma; Zenith Epigenetics
- 15 Apr 2024 Planned End Date changed from 1 Sep 2024 to 1 Jun 2025.
- 15 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
- 19 Feb 2022 Trial design presented at the 2022 Genitourinary Cancers Symposium